FY2025 · period end Jun '25 · from the 10-K filed Nov 10, 2025
| Metric | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 | FY21Jun '21 |
|---|---|---|---|---|---|
| Revenue | $0.34B | $0.46B | $0.42B | $0.33B | $0.21B |
| Gross Profit | $0.13B | $0.19B | $0.18B | $0.13B | $0.09B |
| Operating Income | negative: -$0.00B | $0.05B | $0.05B | $0.04B | $0.04B |
| Net Income | — | — | — | — | — |
| EPS (Diluted) | negative: -$0.88 | $0.07 | $0.30 | negative: -$0.17 | negative: -$0.18 |
| Metric | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 | FY21Jun '21 |
|---|---|---|---|---|---|
| Total Assets | $0.76B | $0.85B | $0.82B | $0.52B | $0.39B |
| Total Liabilities | $0.47B | $0.50B | $0.49B | $0.36B | $0.30B |
| Stockholders' Equity | $0.30B | $0.35B | $0.33B | $0.16B | $0.09B |
| Cash & Equivalents | $0.03B | $0.04B | $0.05B | $0.03B | $0.04B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 | FY21Jun '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $0.05B | $0.04B | $0.00B | negative: -$0.02B | negative: -$0.01B |
| Capital Expenditures | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Free Cash Flow | $0.04B | $0.03B | negative: -$0.01B | negative: -$0.02B | negative: -$0.01B |
| Metric | FY25Jun '25 | FY24Jun '24 | FY23Jun '23 | FY22Jun '22 | FY21Jun '21 |
|---|---|---|---|---|---|
| Gross Margin | 39.3% | 40.1% | 43.9% | 37.8% | 43.4% |
| Operating Margin | negative: -0.0% | 0.1% | 0.1% | 0.1% | 0.2% |
| Net Margin | 0.4% | 0.4% | 0.5% | 0.3% | 0.4% |
| Return on Equity | 42.8% | 54.8% | 77.4% | 93.5% | 118.6% |
| Return on Assets | 17.1% | 22.4% | 28.3% | 25.4% | 25.9% |
| Debt / Equity | 0.53× | 0.51× | 0.51× | 0.92× | 1.38× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 20-F | 0001104659-25-108999 | Jun 30, 2025 | Nov 10, 2025 | Nov 10, 2025 17:26 UTC | EDGAR |
| 20-F | 0001104659-24-112589 | Jun 30, 2024 | Oct 30, 2024 | Oct 30, 2024 19:19 UTC | EDGAR |
| 20-F | 0001104659-23-117743 | Jun 30, 2023 | Nov 14, 2023 | Nov 14, 2023 13:41 UTC | EDGAR |
| 20-F | 0001104659-22-112548 | Jun 30, 2022 | Oct 28, 2022 | Oct 28, 2022 21:21 UTC | EDGAR |
| 20-F | 0001104659-21-131663 | Jun 30, 2021 | Oct 29, 2021 | Oct 29, 2021 17:51 UTC | EDGAR |
| 20-F | 0001104659-20-116812 | Jun 30, 2020 | Oct 21, 2020 | Oct 21, 2020 20:55 UTC | EDGAR |
| 20-F | 0001104659-19-056111 | Jun 30, 2019 | Oct 24, 2019 | Oct 24, 2019 19:47 UTC | EDGAR |
Direct links to SEC EDGAR. BIOX has additional filings available on the SEC site.
6 numbers Bioceres Crop Solutions Corp. later changed — same XBRL tag, both filings linked.
OperatingCashFlow·Q2 2019
Major restatementwas$6.3M
Revised down. Any P/OCF built on the original was 1224.8% too low.
OperatingIncome·Q2 2024
Major restatementwas$7.9M
Revised up.
NetIncomeToCommon·FY 2024
Major restatementwas$3.2M
Revised up in a 20-F.
OperatingCashFlow·FY 2020
Major restatementwas$11.4M
Revised down in a 20-F. Any P/OCF built on the original was 22.6% too low.
PretaxIncome·FY 2024
Major restatementwas$10M
Revised up in a 20-F.
GrossProfit·Q2 2024
Notable restatementwas$45.1M
Revised down.
BIOX is not the only one.
See every restatement we've found across the market — or get an alert the next time BIOX revises a number.
Restatements are detected by comparing every vintage of a fact across all of Bioceres Crop Solutions Corp.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows BIOX's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling Bioceres Crop Solutions Corp. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on BIOX yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on BIOX and publish the result to your public profile.
Ask about Bioceres Crop Solutions Corp.
Continue in Workspace — cited answers on BIOX, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs